An Expanded Access Program of ruxolitinib in COVID-19 associated ARDS
Latest Information Update: 30 Mar 2021
At a glance
- Drugs Ruxolitinib (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Expanded access; Therapeutic Use
- 30 Mar 2021 New trial record
- 18 Mar 2021 According to an Incyte Corporation media release, the company is in discussion with US FDA to make ruxolitinib available to eligible patients in the United States at no cost via an Expanded Access Program (EAP).